CorMedix vs Xeris Biopharma
CRMD and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRMD and XERS compare
Xeris Biopharma is the larger company, worth 8.4 times as much as CorMedix ($3.0B against $363M).
CorMedix grew revenue faster over the last twelve months (92.5% versus 38.4% for Xeris Biopharma).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 15.5% compared with −1.8% at Xeris Biopharma.
CorMedix scores higher on the StockData Score (15 against 11 for Xeris Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRMD | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $363M | $3.0B |
| Share price | $4.66 | $16.66 |
| Change, 1 year | −59.2% | 119% |
| Change, 5 years | −9.2% | 634% |
| Beta (5Y) | 1.37 | 1.15 |
| Employees | 191 | 435 |
| StockData Score | ||
| Total score | 15 (better) | 11 |
| Valuation score | 3 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 4 | 4 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 8.2× |
| P/B | 0.8× (better) | 62.3× |
| EV/EBITDA | 0.1× (better) | 64.4× |
| P/FCF | 1.2× | – |
| FCF yield | 84.8% | – |
| Fair value | $34.62 | $3.65 |
| Margin of safety | 86.5% (better) | −357% |
| Growth | ||
| Revenue growth (TTM) | 92.5% (better) | 38.4% |
| Revenue growth, 5Y average | 320% (better) | 70.2% |
| Net income growth (TTM) | −60.7% | – |
| Profitability | ||
| Gross margin | 77.5% | 87.4% (better) |
| Operating margin | 38.6% (better) | 12.7% |
| Net margin | 15.5% (better) | −1.8% |
| FCF margin | 74.6% | – |
| Return on equity | 15.3% (better) | −27.1% |
| Return on invested capital | 37.4% (better) | 31.5% |
| Financial health | ||
| Debt / equity | 0.00 | 3.89 (better) |
| Net debt / EBITDA | – | 1.22 |
| Interest coverage | – | 1.7× |
| Current ratio | 2.43 (better) | 2.15 |
| Altman Z-score | 1.69 | 4.26 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | −3.1% | – |
| Shareholder yield | −3.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 56.5% | 59.4% |
| Held by insiders | 3.2% | 5.2% |
| Insider net buying, 12 months | −$2.0M (better) | −$5.8M |
| Short interest, % of float | 18.8% | 5.2% |
Go deeper
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.